--- title: "📈 Beginner’s Guide to why Moderna flys : Why Can a Stock Rise Because of a Catalyst?" type: "Topics" locale: "en" url: "https://longbridge.com/en/topics/100000000862087.md" description: "A catalyst is an event or piece of news that can change how investors think about a company’s future.Think of it simply:Good news → better expectations → more buyers → potentially higher stock priceTh..." datetime: "2026-08-20T03:40:59.000Z" locales: - [en](https://longbridge.com/en/topics/100000000862087.md) - [zh-CN](https://longbridge.com/zh-CN/topics/100000000862087.md) - [zh-HK](https://longbridge.com/zh-HK/topics/100000000862087.md) author: "[optionspuppy](https://longbridge.com/en/profiles/20627341.md)" generator: "portal-rs" --- # 📈 Beginner’s Guide to why Moderna flys : Why Can a Stock Rise Because of a Catalyst? A **catalyst** is an event or piece of news that can change how investors think about a company’s future. Think of it simply: **Good news → better expectations → more buyers → potentially higher stock price** The recent news involving Merck & Co. and Moderna is a good example of how a catalyst can affect a stock. ### **🧬 1. What was the catalyst?** Merck and Moderna announced positive results from their Phase 3 **INTerpath-001** clinical trial. The trial tested **intismeran autogene**, an individualized neoantigen therapy, together with **Keytruda**, in patients with completely resected stage IIB-IV melanoma. $Moderna(MRNA.US) The important news for investors was that the trial **met its primary endpoint of recurrence-free survival**. In simple English: 👉 Patients receiving the combination treatment had a substantially lower risk of their cancer returning or dying compared with the standard adjuvant treatment. For a pharmaceutical company, this can be extremely important news. ### **🚀 2. Why can this make a stock rise?** Before the announcement, investors had uncertainty. They might have been thinking: “Will this treatment actually work?” A successful Phase 3 result provides important evidence that the treatment can work in the intended patient population. So investors may start thinking: **Successful trial**⬇️**Potential regulatory submission**⬇️**Potential approval**⬇️**Potential commercial launch**⬇️**Potential new revenue**⬇️**Potentially higher future earnings** The stock price can rise because investors are **pricing in the possibility of better future business performance**. ### **💰 3. Stocks are about the future** This is one of the most important lessons for a beginner. The stock market isn’t only asking: “How much money did the company make today?” It is also asking: **“How much money could this company make in the future?”** Imagine Moderna has a new cancer treatment that could eventually generate billions of dollars in revenue. Even if the treatment generates **$0 in sales today**, investors may still value the company more highly because the probability of future revenue has increased. That’s why a stock can jump immediately after important news. ### **🧪 4. Why is Phase 3 such an important catalyst?** Drug development generally happens through several stages. #### **Phase 1 📝** Researchers primarily look at **safety** and how the treatment behaves in people. #### **Phase 2 🔬** Researchers gather more evidence about **safety, dosage and whether the treatment appears to work**. #### **Phase 3 🎓** The treatment is tested in a much larger population to determine whether it provides meaningful benefits compared with existing treatment. Therefore, a successful Phase 3 trial can be a **major milestone**. However: ⚠️ **Phase 3 success does NOT automatically mean the drug is approved.** The companies still need to submit their data and go through the regulatory process. ### **📜 5. The next catalyst: Regulatory submission** This is another important part of the announcement. Merck and Moderna said they plan to engage with regulatory authorities regarding **submission filings** for the combination therapy. For investors, this creates another potential catalyst. The sequence could look like this: **Phase 3 success** ✅⬇️**Regulatory submission** 📄⬇️**Regulatory review** 🔍⬇️**Potential approval** ✅⬇️**Commercialisation** 💰 Each stage can potentially create new information for investors. ### **📈 6. Why could Moderna benefit?** For Moderna, investors may see this as evidence that its **mRNA technology could have applications beyond COVID-19 vaccines**. That can potentially change the company’s long-term story. Instead of investors thinking only about existing products, they may start thinking about: 🧬 Cancer treatments🧬 Personalized medicine🧬 Future mRNA therapies🧬 Additional clinical programs🧬 Potential future revenue If investors believe the probability of successful commercialization has increased, they may be willing to pay more for the stock. ### **💊 7. Why could Merck benefit?** Merck’s **Keytruda** is already an important cancer treatment. The positive trial result involves using intismeran autogene **in combination with Keytruda**. Therefore, investors may see potential for Keytruda to participate in another important treatment combination. That can potentially strengthen the long-term value of Merck’s oncology business. ### **🧠 8. But here’s the BIG beginner lesson** **Good news doesn’t automatically mean the stock will rise.** Why? Because the stock market cares about **expectations**. Imagine: Investors expect a company to earn **$5.00 per share**. The company announces: **Actual earnings = $5.20** That sounds great! But imagine investors were expecting **$5.50**. The stock could still fall. Why? Because the result was **better than last year but worse than expected**. This is called the difference between: **📊 Actual results vs. Market expectations** ### **🔥 9. A catalyst can also be “better than expected”** For example: **Company A** Expected: Phase 3 succeedsActual: Phase 3 succeeds ➡️ Good news, but perhaps already priced into the stock. **Company B** Expected: Phase 3 has modest resultsActual: Phase 3 dramatically exceeds expectations ➡️ Potentially much stronger catalyst. This is why stocks sometimes explode higher after news. The market is constantly asking: **“Is this better or worse than what we already expected?”** ### **⚠️ 10. Don’t chase the stock just because of the headline** This is where I would be careful as a beginner investor. If I see: **“Company announces successful clinical trial!”** I wouldn’t immediately think: “BUY!” Instead, I would ask: **1️⃣ How important is the news?** Does it actually change the company’s future? **2️⃣ Was it better than expected?** Or did investors already expect success? **3️⃣ How big could the market be?** Could this treatment eventually generate meaningful revenue? **4️⃣ What happens next?** Regulatory submission? Approval? Commercial launch? **5️⃣ Has the stock already jumped 30%, 50% or 100%?** If so, some of the good news may already be reflected in the price. ### **🐶 My Simple Catalyst Formula** I like to simplify it like this: **CATALYST ➡️ Does it change the company’s future? ➡️ Can it increase revenue? ➡️ Can it increase future profits/cash flow? ➡️ Is the news better than expected? ➡️ Is the current valuation still reasonable?** If the answers are mostly **YES**, investors may have a reason to value the company more highly. ### **📌 Final takeaway** A stock doesn’t rise simply because the news is “good.” It rises when the news can make investors believe: **“This company may be worth more in the future than I previously thought.”** The Merck/Moderna Phase 3 result is a good example. **Positive clinical result** 🧬→ reduces uncertainty→ increases confidence in the treatment→ creates potential regulatory opportunity→ creates potential future commercial revenue→ potentially increases the company’s future value→ investors may buy the stock→ **stock price can rise** 📈 But remember: **clinical success is not guaranteed approval, and approval is not guaranteed commercial success.** **Disclaimer:** This is for educational purposes only and is not financial advice. A catalyst can cause a stock to rise, but it can also be followed by profit-taking, volatility or a decline if the market believes the news was already priced in. ### Related Stocks - [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md) - [MRK.US](https://longbridge.com/en/quote/MRK.US.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**